SG11201809982RA - Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents - Google Patents
Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agentsInfo
- Publication number
- SG11201809982RA SG11201809982RA SG11201809982RA SG11201809982RA SG11201809982RA SG 11201809982R A SG11201809982R A SG 11201809982RA SG 11201809982R A SG11201809982R A SG 11201809982RA SG 11201809982R A SG11201809982R A SG 11201809982RA SG 11201809982R A SG11201809982R A SG 11201809982RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- formula
- maryland
- pct
- applicant
- Prior art date
Links
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical class CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 title abstract 2
- 238000001959 radiotherapy Methods 0.000 title abstract 2
- 239000000126 substance Substances 0.000 title abstract 2
- 239000012216 imaging agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 150000001408 amides Chemical class 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 abstract 1
- 241000282887 Suidae Species 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- -1 ester amide Chemical class 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910052709 silver Inorganic materials 0.000 abstract 1
- 239000004332 silver Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B29/00—Monoazo dyes prepared by diazotising and coupling
- C09B29/24—Monoazo dyes prepared by diazotising and coupling from coupling components containing both hydroxyl and amino directing groups
- C09B29/28—Amino naphthols
- C09B29/30—Amino naphtholsulfonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662333427P | 2016-05-09 | 2016-05-09 | |
| PCT/US2017/031696 WO2017196806A1 (en) | 2016-05-09 | 2017-05-09 | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809982RA true SG11201809982RA (en) | 2018-12-28 |
Family
ID=60267260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809982RA SG11201809982RA (en) | 2016-05-09 | 2017-05-09 | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10696631B2 (enExample) |
| EP (1) | EP3455206B1 (enExample) |
| JP (1) | JP6946342B2 (enExample) |
| CN (1) | CN109153641B (enExample) |
| SG (1) | SG11201809982RA (enExample) |
| WO (1) | WO2017196806A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3310758A1 (en) | 2015-06-22 | 2018-04-25 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Chemical conjugates of evans blue derivatives and their use in the production of long-acting therapeutics |
| EP3692032B1 (en) * | 2017-10-03 | 2024-06-19 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents |
| IL276653B2 (en) * | 2018-02-22 | 2024-11-01 | Us Health | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer |
| TWI745616B (zh) * | 2018-09-10 | 2021-11-11 | 行政院原子能委員會核能研究所 | 放射線標誌長效型靶向性胜肽藥物及其生產方法 |
| CN109485642A (zh) * | 2018-11-21 | 2019-03-19 | 希施生物科技（上海）有限公司 | 一种制备伊文氏蓝衍生物的方法 |
| EP3918006A2 (en) * | 2019-01-30 | 2021-12-08 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Conjugates of bivalent evans blue dye derivatives and methods of use |
| EP3906947A4 (en) * | 2019-05-24 | 2022-07-13 | Peking University | TARGETED RADIOPHARMACEUTICALS FOR TUMOURS, AND MULTIPLE THERAPY FOR TARGETED RADIOTHERAPY THEREOF, AND IMAGE-EDITED IMMUNOTHERAPY |
| WO2021177390A1 (ja) * | 2020-03-04 | 2021-09-10 | 日本メジフィジックス株式会社 | 化合物及び放射性標識化合物 |
| MX2022013783A (es) * | 2020-05-06 | 2023-04-19 | Univ Cornell | Compuestos tratanosticos que contienen cobre y metodos de uso. |
| CN114790193B (zh) * | 2020-12-21 | 2024-05-10 | 苏州药明博锐生物科技有限公司 | 成纤维细胞活化蛋白抑制剂 |
| CA3210863C (en) * | 2021-02-10 | 2024-06-04 | Yantai Lannacheng Biotechnology Co., Ltd. | Truncated evans blue modified fibroblast activation protein inhibitor, preparation method and application thereof |
| CN114369084B (zh) * | 2021-02-10 | 2023-02-03 | 烟台蓝纳成生物技术有限公司 | 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用 |
| CN113004371A (zh) | 2021-03-01 | 2021-06-22 | 上海蓝纳成生物技术有限公司 | 一种长循环半衰期的前列腺特异性膜抗原靶向化合物及其制备方法和应用 |
| CN114796532A (zh) * | 2022-04-20 | 2022-07-29 | 北京先通国际医药科技股份有限公司 | 放射性标记的伊文思蓝衍生物药物水溶液及其用途 |
| CN119343151A (zh) * | 2022-06-10 | 2025-01-21 | 北京大学 | 一种三功能化合物及其用途 |
| CN115433261B (zh) * | 2022-11-07 | 2023-01-13 | 烟台蓝纳成生物技术有限公司 | 一种rgd二聚体化合物及其制备方法和应用 |
| CN115583989B (zh) * | 2022-12-09 | 2023-02-28 | 烟台蓝纳成生物技术有限公司 | 一种靶向sstr2的化合物及其制备方法和应用 |
| CN115611779A (zh) * | 2022-12-21 | 2023-01-17 | 北京先通国际医药科技股份有限公司 | 一种放射性药物前体的中间体的制备方法及其用途 |
| CN115838393B (zh) * | 2023-02-16 | 2023-05-05 | 烟台蓝纳成生物技术有限公司 | 用于fapi合成的中间体及其制备方法和应用 |
| CN115850367B (zh) * | 2023-03-02 | 2023-05-23 | 北京先通国际医药科技股份有限公司 | Psma抑制剂的纯化方法及其用途 |
| CN115947775B (zh) * | 2023-03-13 | 2023-06-09 | 北京先通国际医药科技股份有限公司 | 一种制备化合物（i）的方法和化合物（i）及其用途 |
| WO2024240251A1 (zh) * | 2023-05-24 | 2024-11-28 | 北京昌平实验室 | 一种新的三功能化合物及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1598082A4 (en) | 2003-02-27 | 2008-11-12 | Univ Kyushu Nat Univ Corp | CONTRASTANT FOR NUCLEAR PENTOMOGRAPHY |
| JPWO2006025304A1 (ja) | 2004-08-30 | 2008-05-08 | 国立大学法人九州大学 | 動脈硬化検知用ｍｒｉ造影剤 |
| JP2010539163A (ja) * | 2007-09-14 | 2010-12-16 | ヘルス リサーチ インコーポレイテッド | 腫瘍イメージング及び治療用のマルチモーダル剤 |
| US8143219B2 (en) * | 2008-02-26 | 2012-03-27 | Cornell University | Methods for prevention and treatment of acute renal injury |
| CN101623504A (zh) * | 2008-07-07 | 2010-01-13 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 伊文思蓝作为实体肿瘤着色剂的用途 |
| CN103242255B (zh) * | 2013-04-28 | 2015-01-14 | 厦门大学 | 伊文氏蓝配合物及其制备方法和应用 |
| CN104650217B (zh) * | 2015-01-26 | 2018-08-10 | 莎穆(上海)生物科技有限公司 | 伊文氏蓝或其衍生物修饰的Exendin-4及其制备方法和应用 |
| US20160287730A1 (en) | 2015-03-31 | 2016-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Labeled evans blue dye derivative for in vivo serum albumin labeling |
| EP3310758A1 (en) * | 2015-06-22 | 2018-04-25 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Chemical conjugates of evans blue derivatives and their use in the production of long-acting therapeutics |
| WO2017192874A1 (en) | 2016-05-04 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Albumin-binding immunomodulatory compositions and methods of use thereof |
| EP3692032B1 (en) | 2017-10-03 | 2024-06-19 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents |
| IL276653B2 (en) | 2018-02-22 | 2024-11-01 | Us Health | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer |
-
2017
- 2017-05-09 JP JP2018558662A patent/JP6946342B2/ja active Active
- 2017-05-09 EP EP17796666.0A patent/EP3455206B1/en active Active
- 2017-05-09 SG SG11201809982RA patent/SG11201809982RA/en unknown
- 2017-05-09 CN CN201780029003.XA patent/CN109153641B/zh active Active
- 2017-05-09 US US16/099,488 patent/US10696631B2/en active Active
- 2017-05-09 WO PCT/US2017/031696 patent/WO2017196806A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017196806A1 (en) | 2017-11-16 |
| JP2019519491A (ja) | 2019-07-11 |
| US20190084931A1 (en) | 2019-03-21 |
| EP3455206B1 (en) | 2020-11-04 |
| CN109153641A (zh) | 2019-01-04 |
| JP6946342B2 (ja) | 2021-10-06 |
| EP3455206A1 (en) | 2019-03-20 |
| US10696631B2 (en) | 2020-06-30 |
| EP3455206A4 (en) | 2019-11-27 |
| CN109153641B (zh) | 2022-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809982RA (en) | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201908650PA (en) | Optimized antibody compositions for treatment of ocular disorders | |
| SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| SG11201811712QA (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201906543RA (en) | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11202000266VA (en) | Quinoline derivatives for treating infections with helminths | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201808003RA (en) | Bromodomain inhibitors | |
| SG11201909793YA (en) | AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201810561YA (en) | Liquid neurotoxin formulation stabilized with tryptophan or tyrosine | |
| SG11201808830YA (en) | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201903431SA (en) | Sstr-targeted conjugates and particles and formulations thereof | |
| SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases |